Curious ECYT comment from Cowen analyst: http://online.wsj.com/article/SB10001424052702304432704577347541338400490.html Cowen analyst Simos Simeonidis said… “We like Merck as a partner, since it has the bandwidth and know-how to make the most of this compound.” In oncology, is there any Big Pharma with less proficiency than MRK?